Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castrate-resistant Prostate Cancer (CRPC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01646684
What this trial is testing

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
Novartis Pharmaceuticals 9
Early research (Phase 1)Study completedNCT01884285
What this trial is testing

AZD8186 First Time In Patient Ascending Dose Study

Who this might be right for
Advanced Castrate-resistant Prostate Cancer CRPCSquamous Non-Small Cell Lung Cancer sqNSCLCTriple Negative Breast Cancer TNBC
AstraZeneca 147
Testing effectiveness (Phase 2)Study completedNCT01540071
What this trial is testing

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
Io Therapeutics 38
Testing effectiveness (Phase 2)Study completedNCT01468532
What this trial is testing

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Barbara Ann Karmanos Cancer Institute 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06836726
What this trial is testing

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
University Health Network, Toronto 35
Testing effectiveness (Phase 2)Looking for participantsNCT05914116
What this trial is testing

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
DualityBio Inc. 862
Large-scale testing (Phase 3)Looking for participantsNCT07200830
What this trial is testing

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Who this might be right for
Metastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology 1,524
Not applicableStudy completedNCT02376296
What this trial is testing

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Saladax Biomedical, Inc. 35
Early research (Phase 1)Study completedNCT02833883
What this trial is testing

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Who this might be right for
Prostate CancerCastration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT07285694
What this trial is testing

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc. 190
Testing effectiveness (Phase 2)Active Not RecruitingNCT02807805
What this trial is testing

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
Mamta Parikh 37
Very early researchActive Not RecruitingNCT06228404
What this trial is testing

Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

Who this might be right for
Metastatic Castration-resistant Prostate CancerCastration-resistant Prostate Cancer
Shanghai Changzheng Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT06549465
What this trial is testing

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics 93
Testing effectiveness (Phase 2)Ended earlyNCT03690141
What this trial is testing

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Who this might be right for
Castrate-resistant Prostate Cancer (CRPC)
Effector Therapeutics 16
Not applicableStudy completedNCT02380274
What this trial is testing

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate CancerCastration-resistant Prostate CancerMetastatic Prostate Cancer
Astellas Pharma Global Development, Inc. 1,030
Large-scale testing (Phase 3)Study completedNCT04676334
What this trial is testing

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

Who this might be right for
Metastatic Castration-Resistant Prostate CancerOvarian CancerEpithelial Ovarian Cancer+3 more
pharmaand GmbH 34
Not applicableStudy completedNCT02669147
What this trial is testing

Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC

Who this might be right for
Castration Resistant Prostate Cancer (CRPC)
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 160
Testing effectiveness (Phase 2)WithdrawnNCT05445882
What this trial is testing

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT01026623
What this trial is testing

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate Carcinoma+1 more
National Cancer Institute (NCI) 16
Large-scale testing (Phase 3)Ended earlyNCT01083615
What this trial is testing

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castrate-Resistant Prostate CancerHormone Refractory Prostate Cancer
Achieve Life Sciences 14
Next Page